Business Wire

Exscientia Initiates Prospective Observational Study in Ovarian Cancer

18.7.2023 14:00:00 EEST | Business Wire | Press release

Share

Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response (EVDR) in primary tumour-derived samples using the company’s precision medicine platform and actual patient clinical response. This first of its kind observational study in solid tumours will run at multiple medical research centres in Europe with a focus on ovarian cancers. It aims to inform and enable future studies in other solid tumours.

Ovarian cancer represents a high unmet need for predicting patient response to diverse therapy options. The study will be conducted in collaboration with the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, one of the leading non-profit clinical research networks in gynaeco-oncology worldwide.

“We are thrilled to work with Exscientia to advance the state of science and potential treatment of ovarian cancer patients," said Professor Philipp Harter M.D., Ph.D., Head of Gynaecology and Gynaeco-Oncology at Evangelische Kliniken Essen-Mitte, Germany, and Chair of the AGO Study Group. "This study will enable us to explore new ways to identify the right treatment for individual patients, especially in cases with no available molecular biomarkers. We look forward to being a part of this important scientific evaluation.”

By combining high-content imaging of samples and deep learning image analysis, the company’s AI-based precision medicine platform leverages a patient’s biopsies to assess drug activity at a single cell level ex vivo. The EXCYTE-1 trial follows the prospective EXALT-1 trial in haematologic malignancies, the first study to leverage AI-driven ex vivo drug testing to guide treatment selection and improve outcomes in patients with advanced haematological cancers. Patients who received drugs prioritised by the platform experienced significantly better outcomes, with 54% of patients demonstrating clinical benefit of >1.3-fold enhanced progression free survival (PFS) compared to prior therapy. The EXCYTE-1 trial is designed to expand the scope of Exscientia’s precision medicine platform in solid tumours.

“The outcomes from this study could have broad implications for how we evaluate drug candidates and support clinical practice in the future,” said Dr. Nikolaus Krall, EVP of Precision Medicine at Exscientia. “If established, a robust correlation between our platform’s results and clinical outcomes will support the greater use of human tumour samples in the preclinical development of new drug candidates and translational cancer research. This has the potential to overcome the limited clinical relevance of mouse and other animal models that are presently used. In addition, this study may further pave the way for the use of functional drug testing to guide treatment selection to achieve better patient outcomes.”

About EXCYTE-1 Prospective Observational Study

The EXCYTE-1 trial is a multi-centre two-phase study evaluating the correlation between clinical and ex vivo drug response as measured using Exscientia’s AI-based precision medicine platform in ovarian cancer. The study is designed to compare results from the precision medicine platform to clinical outcomes via tissue collection and drug response analysis.

The objective of the pilot phase of the study is to collect patient tissue samples and analyse the drug response of the tissue in a lab setting before scaling up to a larger expansion phase. Two patient populations will be included: patients newly diagnosed with advanced ovarian cancer and those with relapsed ovarian cancer. Before undergoing therapy, malignant ascites will be collected, accompanied by solid tissues where available. The EVDR of commonly used standard of care therapies will then be evaluated in these patient samples by Exscientia’s AI-based precision medicine platform. These results will be compared against patients’ clinical response to treatment, which will be chosen and evaluated by physicians blinded to the EVDR data. Progression free survival (PFS) of patients will be monitored as the key clinical endpoint and assessed to monitor association with EVDR. Secondary endpoints will include EVDR predicted early relapse and PFS >12 months.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Exscientia Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the collaboration with the AGO Study Group; and the timing and progress of, and data collected during and reported from, the EXCYTE-1 clinical trial, as well as expectations with respect to the outcome or benefit of such trial. Any statement describing Exscientia’s goals, plans, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Sara Sherman
investors@exscientia.ai

Media:
Oliver Stohlmann
media@exscientia.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 18:30:00 EET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 17:24:00 EET | Press release

When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 17:04:00 EET | Press release

North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 16:32:00 EET | Press release

Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally required paying to reach them again. Meanwhile, direct web sales have become a major revenue ch

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 16:10:00 EET | Press release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye